FDA approves Moderna's mRNA influenza vaccine, the first of its kind
The US Food and Drug Administration has licensed mFluSIva, Moderna's messenger RNA flu shot, marking the first regulatory approval of mRNA technology for influenza.
Cross-source consensus on what matters today in genetics and genomics — drawn from 16 trusted public sources including NHGRI, the CDC, NHS England, Genomics England, the PHG Foundation, the Wellcome Sanger Institute, and peer-reviewed open-access journals.
Last updated: · browse archive
The US Food and Drug Administration has licensed mFluSIva, Moderna's messenger RNA flu shot, marking the first regulatory approval of mRNA technology for influenza.
Aurora Therapeutics, which aimed to industrialise bespoke CRISPR gene-editing treatments modelled on the Baby KJ case, has abandoned its programme, citing regulatory demands that a small company could not meet.
A preprint analysing genome-wide data from the Arras Culture of Middle Iron Age northeast England, including 390 individuals from Wetwang, finds evidence for matrilineal descent and recurrent unions between dominant matrilines.
A delayed report of a second fatality in an investigator-led gene-editing study in China has intensified international debate about oversight standards and trial transparency.
A preprint mouse study finds that diet and exercise reversal in obese male mice reshapes sperm RNA profiles and partially protects the next generation from metabolic disorders, suggesting an epigenetic mechanism for intergenerational inheritance.
A study finds that stable circular RNA derived from mobile genetic elements may provide a previously unrecognised route for transposable elements to move between bacterial species.
A preprint reports that locus-specific activation of transposable elements in UBA1-mutant haematopoietic stem cells may drive the complex inflammatory and clonal features of VEXAS syndrome.
Using longitudinal proteomics data from two major cohorts, researchers have begun mapping which genetic variants influence how protein abundances shift with age across diverse individuals.
A new study proposes that the intense transcriptional activity of cancer superenhancers inflicts recurrent DNA double-strand breaks, with imperfect repair generating the mutations that fuel tumour evolution.
A preprint integrating DNA methylation data across 20 solid cancers finds that epigenetic age acceleration is not uniform — some tumour types appear younger than matched normal tissue, others older.
About Genetic Current
Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.
Join the Evagene Alpha Waiting List